• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc. - Common Stock (NQ:LTRN)

    0.8601 -0.1399 (-13.99%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 432,254
    Open 1.030
    Bid (Size) 0.8610 (300)
    Ask (Size) 0.8700 (2,600)
    Prev. Close 1.000
    Today's Range 0.8375 - 1.040
    52wk Range 0.9700 - 4.703
    Shares Outstanding 11,184,423
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Closes $4 Million Registered Direct Offering
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
    From Lantern Pharma Inc.
    Via Business Wire

    Performance

    52-Week Range 81.7% below 52-week high
    0.8601
    0.9752W Low 4.7052W High
    1 Week 32.8% below 1-week high
    0.971W Low 1.281W High

    Lantern Pharma Inc. - Common Stock (LTRN) traded between $0.97 and $4.70 over the past 52 weeks and last traded at $0.86, 81.7% below its 52-week high. Over the past week it ranged between $0.97 and $1.28.

    Past 12 Months
    -29.5%
    -57.4%
    -78.3%
    -46.9%
    -72.3%
    -79.1%
    1W -$0.36
    1M -$1.16
    3M -$3.11
    6M -$0.76
    YTD -$2.25
    1Y -$3.26

    LTRN was -79.1% over the past year, -46.9% over six months, -72.3% year to date, -29.5% in the last week.

    12 Months vs Market
    LTRN
    -79.1%
    DIA
    +10.1%
    SPY
    +15.1%
    QQQ
    +24.3%
    IWM
    +16.1%

    Over the past 12 months LTRN returned -79.1% versus DIA (Dow) +10.1%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +16.1%.

    Volume & Liquidity 2.47× 3-mo avg
    Today 432,254 3-mo avg 174.8K
    1W
    344.0K
    1M
    274.4K
    3M
    174.8K
    6M
    228.3K
    YTD
    314.0K
    1Y
    259.4K

    LTRN most recently traded 432,254 shares against a 3-month average daily volume of 174.8K.

    More News

    Read More
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Announces $4 Million Registered Direct Offering
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
    From New to The Street
    Via ACCESS Newswire
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) to Present Open-Medicine AI Growth Plan, Live Platform Demo in Webinar
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
    From Lantern Pharma Inc.
    Via Business Wire
    MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
    From New to The Street
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Show 771 Airs Today on Bloomberg, Featuring Bill Mobley, Panna Sharma, Phillip Toppino and Dr. Kelley Gurley
    From New to The Street
    Via ACCESS Newswire
    News headline image
    New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)
    From New to The Street
    Via ACCESS Newswire
    News headline image
    New to The Street Broadcasting Today at 6:30 PM EST on Bloomberg Television Across the U.S., Latin America and MENA-Featuring FreeCast (NASDAQ: CAST), Metaterra Holdings (MTHI) and SafeSpace Global (SGCC)
    From New to The Street
    Via ACCESS Newswire
    News headline image
    Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    NetworkNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Advances AI-Driven Oncology Pipeline, Establishes Open Medicine AI
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street Show 766 Broadcasts Tonight at 6:30 PM ET on Bloomberg Television, Featuring BioVie's Bezisterim Parkinson's Disease Clinical Results
    From New to The Street
    Via ACCESS Newswire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Schedules Second-Quarter 2026 Results Webcast
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
    From Lantern Pharma Inc.
    Via Business Wire
    News headline image
    New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial
    From New to The Street
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) EMA Clears LP-184 Bladder Cancer Trial in Europe
    Via Investor Brand Network
    Topics Artificial Intelligence
    News headline image
    Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
    From Lantern Pharma Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Lantern Pharma Inc. - Common Stock publicly traded?
    Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
    What exchange does Lantern Pharma Inc. - Common Stock trade on?
    Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
    The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
    What is the current price of Lantern Pharma Inc. - Common Stock?
    The current price of Lantern Pharma Inc. - Common Stock is 0.8601
    When was Lantern Pharma Inc. - Common Stock last traded?
    The last trade of Lantern Pharma Inc. - Common Stock was at 10/02/26 04:00 PM ET
    What is the market capitalization of Lantern Pharma Inc. - Common Stock?
    The market capitalization of Lantern Pharma Inc. - Common Stock is 9.62M
    How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
    Lantern Pharma Inc. - Common Stock has 10M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.